Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Reprogramming & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CS drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human CS Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, Active Enzymatic Conformation. |
View CS Products |
| Gene Delivery | CS Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assay systems. |
View CS Products |
| Benchmark Ab | Anti-CS Benchmark Control Antibody High-affinity recombinant positive control for mitochondrial profiling and ELISA. |
View CS Products |
| Validator | CS siRNA Set For target knockdown verification and background specificity checks. |
View CS Products |
| Related Target A | IDH1 Critical downstream TCA cycle enzyme; synergistic metabolic target in mutated gliomas and AML. |
View IDH1 Products |
| Related Target B | ACLY Cytosolic ATP-citrate lyase linking mitochondrial CS citrate output to de novo lipogenesis in solid tumors. |
View ACLY Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & Background Interference | Recombinant Human CS Protein verified for exact theoretical MW, high purity (>95% by SDS-PAGE), and active enzymology without tag interference. |
| Cross-species Preclinical Screening (Human vs Mouse models) | Human and Mouse ortholog proteins sequence-verified by mass spectrometry and rigorously QC-tested for structural uniformity. |
| Lack of Standardized Controls | Sequence-verified recombinant positive control antibodies and benchmark assay tools included. |
| Target Specificity & False Positives | Validated CS siRNA sets included for specific target depletion and background signal subtraction. |
Live CS (Citrate Synthase) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for targeting cellular metabolism in oncology and neurodegeneration is intensifying, with researchers shifting focus from upstream glycolysis to mitochondrial core engines. Citrate Synthase (CS), as the pacemaker enzyme of the tricarboxylic acid (TCA) cycle, governs the entry of acetyl-CoA into central carbon metabolism. As first-generation metabolic therapies targeting IDH1/2 reach the clinic and establish clinical validation, the next wave of R&D is heavily targeting TCA cycle modulation to combat Warburg effect bypass, metabolic flexibility in refractory solid tumors, and mitochondrial dysfunction in neurodegenerative disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors / Allosteric Modulators | Preclinical Biotech & Academic Consortia | Refractory Solid Tumors & Glioblastoma | High-throughput Enzymatic Screening (Need active, high-purity Recombinant CS without tag steric hindrance) |
| Metabolic Pathway Modulators | Big Pharma Oncology Units | Metastatic & Chemo-resistant Cancers | Cellular Flux & Overexpression Validation (Need sequence-verified Lentivirus for stable cell line construction) |
| Mitochondrial Biomarker & Diagnostic Assays | Diagnostic Developers & CRO Partners | Neurodegenerative Diseases (AD/PD) & Mitochondrial Myopathies | High-sensitivity Profiling & Quantification (Need benchmark recombinant positive control antibodies) |